Effects of fenofibrate or eiocosapentaenoic acid(EPA) on glucose metabolism, fat distribution, adipocytokines and inflammatory cytokines in type 2 Diabetes.

Effects of fenofibrate or eiocosapentaenoic acid(EPA) on glucose metabolism, fat distribution, adipocytokines and inflammatory cytokines in type 2 Diabetes. - FiEPA study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000969

Enrollment

Registered

2008-01-07

Start date

2008-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 Diabetes

Interventions

fenofibrate (100-200mg/day) eicosapentaenoic acid(EPA) (1800mg/day)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: type 2 diabetes mellitus Japanese patients not administered with thiazolidinediones.

Exclusion criteria

Exclusion criteria: 1. Severe hypercholesterolemia(LDL>140mg/dl) 2. Severe deficiency of insulin secretion 3. Severe renal dysfunction (serum creatinin>2.0mg/dl) 4. Severe liver dysfunction (AST, ALT>50IU/ml) 5. Severe herat failure 6. History of hypersensitivity to pioglitazone or metformin. 7. During the pregnancy and nursing 8. Inadequately BS contrilled (FBG>150mg/dl) 9. Inadequate to entry this study

Design outcomes

Primary

Measure	Time frame
1. Evaluation of the effects on glucose metabolism and insulin sensitivity calculated with oral glucose tolerance test before and after 12 weeks treatment. 2. Measurement of the amount visceral fat, intramyocellular lipid content(IMCL) and hepatic lipid content(HLC) before and after 12 weeks treatment.	—

Secondary

Measure	Time frame
3. Measurement of HbA1c, total-cholesterol, LDL-cholesterol, triglyceride, FFA, oxidized LDL, Lipoprotein(a), remnant-like particle lipoorotein(RLP), adipocytokines, inflammatory cytokines, oxidative stress marker before and after 12 weeks treatment. 4. Measurement of body weight and waist before and after 12 weeks treatment.	—

Countries

Japan

Contacts

Public ContactKazuhiko Sakaguchi

Kobe University Graduate School of Medicine Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine

kzhkskgc@med.kobe-u.ac.jp078-382-5861

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026